Literature DB >> 23222898

Characteristics of early and late PTLD development in pediatric solid organ transplant recipients.

Tilmann Schober1, Theodor Framke, Hans Kreipe, Thomas F Schulz, Anika Großhennig, Kais Hussein, Ulrich Baumann, Lars Pape, Stephan Schubert, Anne-Margret Wingen, Thomas Jack, Armin Koch, Christoph Klein, Britta Maecker-Kolhoff.   

Abstract

BACKGROUND: Posttransplantation lymphoproliferative disorders (PTLD) present a major cause of mortality and morbidity after solid organ transplantation. The purpose of this study was to identify the factors associated with the development of early- and late-onset PTLD in pediatric solid organ transplant recipients.
METHODS: We examined the medical history, laboratory parameters, and pathology of 127 children with PTLD who were registered in the German multicenter pediatric PTLD registry. Data were collected retrospectively from 1991 to 2003 and prospectively from 2004 onward. We compared early (<1 year) and late (>1 year) PTLD using survival analysis.
RESULTS: The median time to PTLD was 3.00 (95% confidence interval, 2.12-3.26) years. Forty-two patients developed PTLD within the first year after transplantation (early PTLD) and 85 patients developed PTLD after 1 year (late PTLD). Early PTLD development was associated with younger age (P=0.0016), extranodal disease (P=0.019), graft organ involvement (P=0.0065), and immunosuppressive regimens including tacrolimus (P=0.001) or mycophenolate (P=0.0025). Most early PTLD patients experienced graft rejection before PTLD diagnosis (P=0.0081). Early PTLD was often of B-cell lymphoma histology (P=0.024) and tended to be Epstein-Barr virus positive (P=0.052). In contrast, Burkitt's lymphoma (P=0.0047) and Hodgkin's disease (P=0.016) were only observed in late PTLDs, which are more likely to present with nodal disease (P=0.019). Overall survival and event-free survival were not significantly different between early and late PTLD.
CONCLUSION: Early and late childhood PTLD have distinct characteristics. Whereas early PTLD appears mainly as an Epstein-Barr virus-driven disease especially favored by insufficient immunosurveillance, late PTLD often resembles tumors with distinct pathogenetic alterations and nodal appearance.

Entities:  

Mesh:

Year:  2013        PMID: 23222898     DOI: 10.1097/TP.0b013e318277e344

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  24 in total

1.  Early- and late-onset severe pneumonia after renal transplantation.

Authors:  Guowei Tu; Minjie Ju; Yijun Zheng; Ming Xu; Ruiming Rong; Duming Zhu; Tongyu Zhu; Zhe Luo
Journal:  Int J Clin Exp Med       Date:  2015-01-15

Review 2.  Post-transplantation lymphoproliferative disorders: Current concepts and future therapeutic approaches.

Authors:  Fedaey Abbas; Mohsen El Kossi; Ihab Sakr Shaheen; Ajay Sharma; Ahmed Halawa
Journal:  World J Transplant       Date:  2020-02-28

Review 3.  The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.

Authors:  Olivia M Martinez; Sheri M Krams
Journal:  Transplantation       Date:  2017-09       Impact factor: 4.939

Review 4.  Adoptive cellular immunotherapy for virus-associated cancers: a new paradigm in personalized medicine.

Authors:  Corey Smith; Rajiv Khanna
Journal:  Immunol Cell Biol       Date:  2017-01-10       Impact factor: 5.126

5.  Pediatric Onco-Nephrology: Time to Spread the Word-Part II: Long-Term Kidney Outcomes in Survivors of Childhood Malignancy and Malignancy after Kidney Transplant.

Authors:  Arwa Nada; Jennifer G Jetton
Journal:  Pediatr Nephrol       Date:  2021-09-06       Impact factor: 3.651

Review 6.  Malignancies after pediatric kidney transplantation: more than PTLD?

Authors:  Martin Mynarek; Kais Hussein; Hans H Kreipe; Britta Maecker-Kolhoff
Journal:  Pediatr Nephrol       Date:  2013-09-24       Impact factor: 3.714

Review 7.  Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra.

Authors:  Francesca Montanari; Manuela Orjuela-Grimm
Journal:  Curr Hematol Malig Rep       Date:  2021-02-05       Impact factor: 3.952

8.  Steering Transplant Immunosuppression by Measuring Virus-Specific T Cell Levels: The Randomized, Controlled IVIST Trial.

Authors:  Thurid Ahlenstiel-Grunow; Xiaofei Liu; Raphael Schild; Jun Oh; Christina Taylan; Lutz T Weber; Hagen Staude; Murielle Verboom; Christoph Schröder; Ruxandra Sabau; Anika Großhennig; Lars Pape
Journal:  J Am Soc Nephrol       Date:  2020-12-15       Impact factor: 10.121

Review 9.  Infectious disease risks in pediatric renal transplantation.

Authors:  Felicia A Scaggs Huang; Lara Danziger-Isakov
Journal:  Pediatr Nephrol       Date:  2018-04-06       Impact factor: 3.651

10.  Non-Hodgkin lymphoma after pediatric kidney transplantation.

Authors:  Ryszard Grenda
Journal:  Pediatr Nephrol       Date:  2021-10-11       Impact factor: 3.651

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.